Your browser doesn't support javascript.
loading
In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio.
Gani, Cihan; Coackley, Carla; Kumareswaran, Ramya; Schütze, Christina; Krause, Mechthild; Zafarana, Gaetano; Bristow, Robert G.
Afiliación
  • Gani C; Princess Margaret Cancer Centre (Radiation Medicine Program, University Health Network), Toronto, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Canada; Department of Radiation Oncology, University Hospital of Tuebingen, Germany.
  • Coackley C; Princess Margaret Cancer Centre (Radiation Medicine Program, University Health Network), Toronto, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Canada.
  • Kumareswaran R; Princess Margaret Cancer Centre (Radiation Medicine Program, University Health Network), Toronto, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Canada.
  • Schütze C; OncoRay - National Centre for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Germany; Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Tech
  • Krause M; OncoRay - National Centre for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Germany; Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Tech
  • Zafarana G; Princess Margaret Cancer Centre (Radiation Medicine Program, University Health Network), Toronto, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Canada.
  • Bristow RG; Princess Margaret Cancer Centre (Radiation Medicine Program, University Health Network), Toronto, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Canada. Electronic address: rob.bristow@rmp.uhn.on.ca.
Radiother Oncol ; 116(3): 486-94, 2015 Sep.
Article en En | MEDLINE | ID: mdl-26277432
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Neoplasias de la Próstata / Fármacos Sensibilizantes a Radiaciones / Quimioradioterapia / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Antineoplásicos Límite: Animals / Humans / Male Idioma: En Revista: Radiother Oncol Año: 2015 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Irlanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Neoplasias de la Próstata / Fármacos Sensibilizantes a Radiaciones / Quimioradioterapia / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Antineoplásicos Límite: Animals / Humans / Male Idioma: En Revista: Radiother Oncol Año: 2015 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Irlanda